This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Bone marrow transplantation in thalassaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is not, at present conventional treatment of beta thalassaemia. However results of studies of allogenic bone marrow transplantation by Lucarelli and his colleagues from Pesaro, Italy have been encouraging.

Reported probabilities of survival, rejection-free survival, death unrelated to rejection and rejection were reported at 0.92, 0.85, 0.06, and 0.08 respectively.

  • first successful allogeneic stem cell transplant from an HLA-identical sibling donor was reported in 1982
  • Italian group led by Lucarelli has the most experience with this procedure
    • documented a 90% long-term survival rate in patients with favorable characteristics (young age, HLA match, no organ dysfunction)

Transplantation-related issues such as graft versus host disease, graft failure, chronic immunosuppressive therapy, and transplantation-related mortality are factors that should be carefully considered prior to proceeding with this approach.

Reference:

  • Thomas ED, Buckner CD, Sanders JE, Papayannopoulou T, Borgna-Pignatti C, De Stefano P. Marrow transplantation for thalassaemia. Lancet. Jul 31 1982;2(8292):227-9
  • Lucarelli G, Galimberti M, Polchi P. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. Sep 16 1993;329(12):840-4

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.